Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

Neurobiology of Disease

Volumn 22, Issue 1, 2006, Pages 1-9

  Armentero, Marie Thérèse ^a   Fancellu, Roberto ^a,b   Nappi, Giuseppe ^a,d   Bramanti, Placido ^c   Blandini, Fabio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

6 Hydroxydopamine; Basal ganglia; Cytochrome oxidase; Ionotropic; Metabotropic; Neuroprotection; Rat; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; CYTOCHROME C OXIDASE; DIZOCILPINE; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; BASAL GANGLION; BEHAVIOR; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; EXCITATORY AMINO ACID ANTAGONISTS; MALE; NERVE DEGENERATION; NEURAL PATHWAYS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

EID: 33645090418     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.09.010     Document Type: Article

References (44)

1. J.A. Aguirre, J. Kehr, T. Yoshitake, F.L. Liu, A. Rivera, S. Fernandez-Espinola, B. Andbjer, G. Leo, A.D. Medhurst, L.F. Agnati, and K. Fuxe Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP Brain Res. 1033 2005 216 220
2. M.T. Armentero, R. Fancellu, G. Nappi, and F. Blandini Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat Exp. Neurol. 178 2002 301 305
3. H. Awad, G. Hubert, Y. Smith, A. Levey, and P. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
4. G. Battaglia, C. Buscet, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigrostriatal damage induced in mice J. Neurosci. 24 2004 828 835
5. F. Blandini, and J. Greenamyre Prospects of glutamate antagonists in the therapy of Parkinson's disease Fund. Clin. Pharmacol. 12 1998 4 12
6. F. Blandini, M. Garcia-Osuna, and J. Greenamyre Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats Eur. J. Neurosci. 9 1997 1407 1413
7. F. Blandini, G. Nappi, C. Tassorelli, and E. Martignoni Functional changes of the basal ganglia circuitry in Parkinson's disease Prog. Neurobiol. 62 2000 63 88
8. F. Blandini, G. Nappi, and J. Greenamyre Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease Ann. Neurol. 49 2001 525 529
9. F. Blandini, M.T. Armentero, R. Fancellu, E. Blaugrund, and G. Nappi Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease Exp. Neurol. 187 2004 455 459
10. N. Breysse, M. Amalric, and P. Salin Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats J. Neurosci. 23 2003 8302 8309
11. P. Burbaud, C. Gross, A. Benazzouz, M. Coussemacq, and B. Bioulac Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons Exp. Brain Res. 105 1995 48 58
12. P. Conn, and J. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol Toxicol. 37 1997 205 237
13. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp. Neurol. 175 2002 303 317
14. A. Doherty, M. Palmer, Z. Bortolotto, A. Hargreaves, A. Kingston, P. Ornstein, D. Schoepp, D. Lodge, and G. Collingridge A novel competitive mGluR5 antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices Br. J. Pharmacol. 131 2000 239 244
15. M.R. Domenici, R.L. Potenza, A. Martire, R. Coccurello, A. Pezzola, R. Reggio, M.T. Tebano, and P. Popoli Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease J. Neurosci. Res. 80 2005 646 654
16. L.S. Forno Neuropathology of Parkinson's disease J. Neuropathol. Exp. Neurol. 55 1996 259 272
17. C.R. Honey, and H. Shen Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus Neurosci. Lett. 249 1998 151 154
18. G. Hubert, M. Paquet, and Y. Smith Differential subcellular localization of mGluR1 and mGluR5 in the rat, monkey substantia nigra J. Neurosci. 21 2001 1838 1847
19. D. Kirik, C. Rosenblad, and A. Björklund Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor Eur. J. Neurosci. 12 2000 3871 3882
20. H. Kita, and S. Kitai Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method J. Comp. Neurol. 260 1987 435 452
21. S. Konitsiotis, P.J. Blanchet, L. Verhagen, E. Lamers, and T.N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology 54 2000 1589 1595
22. J. Lee, G. Zipfel, and D. Choi The changing landscape of ischemic brain injury Nature 399 1999 R1 R3
23. M. Marino, M. Wittmann, S. Bradley, G. Hubert, Y. Smith, and P. Conn Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata J. Neurosci. 21 2001 7001 7012
24. B. Meldrum Glutamate as a neurotransmitter in the brain: review of physiology and pathology J. Nutr. 130 2000 1007S 1015S
25. J.E. Nash, M.P. Hill, and J.M. Brotchie Anti-Parkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat Exp. Neurol. 155 1999 42 48
26. K. Ossowska, J. Konieczny, S. Wolfarth, J. Wieronska, and A. Pilc Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rat Neuropharmacology 41 2001 413 420
27. G. Paul, W. Meissner, S. Rein, D. Harnack, C. Winter, K. Hosmann, R. Morgenstern, and A. Kupsch Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease Exp. Neurol. 185 2004 272 280
28. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1998 Academic Press San Diego, USA
29. B. Piallat, A. Benazzouz, and A.L. Benabib Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease J. Neural Transm. 55 1999 71 77 (Suppl.)
30. A. Pisani, P. Calabresi, D. Centonze, and G. Bernardi Enhancement of NMDA responses by group-I metabotropic glutamate receptor activation in striatal neurons Br. J. Pharmacol. 120 1997 1007 1014
31. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587
32. R. Porter, J. Greene, D. Higgins, and J. Greenamyre Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion J. Neurosci. 14 1994 7192 7199
33. M.C. Rodriguez, J.A. Obeso, and C.W. Olanow Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection Ann. Neurol. 44 1998 S175 S188
34. D.N. Ruskin, D.A. Bergstrom, C.W. Mastropietro, M.J. Twery, and J.R. Walters Dopamine agonist-mediated rotation in rats with unilateral nigrostriatal lesions is not dependent on net inhibitions of rate in basal ganglia output nuclei Neuroscience 91 1999 935 946
35. H. Sauer, and W.H. Oertel Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat Neuroscience 59 1994 401 415
36. Y. Smith, A. Charara, and A. Parent Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey J. Comp. Neurol. 364 1996 231 253
37. W. Spooren, F. Gasparini, R. Bergmann, and R. Kuhn Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats Eur. J. Pharmacol. 406 2000 403 410
38. E. Storey, B. Hyman, B. Jenkins, E. Brouillet, J. Miller, B. Rosen, and M.F. Beal MPP+ produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism J. Neurochem. 58 1992 1975 1978
39. N. Turle-Lorenzo, N. Breysse, C. Baunez, and M. Amalric Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease Psychopharmacology 179 2005 117 127
40. L. Turski, K. Bressler, K. Rettig, P. Löschmann, and H. Watchel Protection of substantia nigra from MPP+ neurotoxicity by NMDA antagonists Nature 349 1991 414 418
41. M. Vila, M.-T. Herrero, B. Faucheux, J. Obeso, Y. Agid, and E. Hirsch Metabolic activity of the basal ganglia in Parkinsonian syndromes in human and non-human primate: a cytochrome oxidase histochemistry study Neuroscience 71 1996 903 912
42. M. Vila, C. Marin, M. Ruberg, A. Jimenez, R. Raisman-Vozari, Y. Agid, E. Tolosa, and E.C. Hirsch Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia J. Neurochem. 73 1999 344 352
43. M. Wong-Riley Cytochrome oxidase: an endogenous metabolic marker for neuronal activity Trends Neurosci. 12 1989 94 101
44. A. Zuddas, G. Oberto, F. Vaglini, F. Fascetti, F. Fornai, and G. Corsini MK-801 prevents MPTP-induced parkinsonism in primates J. Neurochem. 59 1991 133 139